Cytodyn Stock Fundamentals
CYDY Stock | USD 0.14 0.01 6.67% |
Cytodyn fundamentals help investors to digest information that contributes to Cytodyn's financial success or failures. It also enables traders to predict the movement of Cytodyn OTC Stock. The fundamental analysis module provides a way to measure Cytodyn's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytodyn otc stock.
Cytodyn |
Cytodyn OTC Stock Shares Owned By Insiders Analysis
Cytodyn's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Cytodyn Shares Owned By Insiders | 7.91 % |
Most of Cytodyn's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytodyn is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition |
Based on the latest financial disclosure, 7.914% of Cytodyn are shares owned by insiders. This is 47.87% lower than that of the Biotechnology sector and 44.19% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 21.57% higher than that of the company.
Cytodyn Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cytodyn's current stock value. Our valuation model uses many indicators to compare Cytodyn value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cytodyn competition to find correlations between indicators driving Cytodyn's intrinsic value. More Info.Cytodyn is rated below average in return on asset category among its peers. It is rated third in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cytodyn by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cytodyn's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cytodyn Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytodyn's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cytodyn could also be used in its relative valuation, which is a method of valuing Cytodyn by comparing valuation metrics of similar companies.Cytodyn is currently under evaluation in shares owned by insiders category among its peers.
Cytodyn Fundamentals
Return On Asset | -1.48 | |||
Current Valuation | 286.7 M | |||
Shares Outstanding | 832.97 M | |||
Shares Owned By Insiders | 7.91 % | |||
Shares Owned By Institutions | 0.06 % | |||
Price To Earning | (3.14) X | |||
Price To Book | 1,066 X | |||
Price To Sales | 1,174 X | |||
Revenue | 266 K | |||
Gross Profit | (73.28 M) | |||
EBITDA | (157.59 M) | |||
Net Income | (210.82 M) | |||
Cash And Equivalents | 4.68 M | |||
Cash Per Share | 0.01 X | |||
Total Debt | 37.35 M | |||
Current Ratio | 0.08 X | |||
Book Value Per Share | (0.14) X | |||
Cash Flow From Operations | (77.72 M) | |||
Earnings Per Share | (0.23) X | |||
Target Price | 4.0 | |||
Number Of Employees | 23 | |||
Beta | 0.2 | |||
Market Capitalization | 233.23 M | |||
Total Asset | 29.18 M | |||
Retained Earnings | (211.86 M) | |||
Working Capital | (371.16 K) | |||
Current Asset | 136.91 K | |||
Current Liabilities | 508.07 K | |||
Z Score | -22.7 | |||
Net Asset | 29.18 M |
About Cytodyn Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytodyn's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytodyn using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytodyn based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.BJRI | BJs Restaurants | |
KLG | WK Kellogg Co | |
JAMF | Jamf Holding |
Additional Tools for Cytodyn OTC Stock Analysis
When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.